ClearB Therapeutics announces a license and collaboration with Adjuvance Technologies to access a novel saponin adjuvant, TQL-1055, and upcoming poster presentations of preclinical chronic hepatitis B data at AASLD 2024.
ClearB Therapeutics announces a license and collaboration with Adjuvance Technologies to access a novel saponin adjuvant, TQL-1055, and upcoming poster presentations of pre-clinical chronic hepatitis B data at AASLD 2024. CONCORD, MA, 17 OCTOBER 2024 — ClearB Therapeutics, Inc., a company developing therapeutic vaccines designed to [...]